Multidrug resistance and its reversal

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 2905-2917

  Volm, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antibodies; Antisense; Chemosensitizer; Clinical trials; Multidrug resistance; Reversal

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALBUMIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BISPECIFIC ANTIBODY; CYCLOSPORIN A; CYTOSTATIC AGENT; DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HEAT SHOCK PROTEIN; IMMUNOTOXIN; METALLOTHIONEIN; MONOCLONAL ANTIBODY; RIBOZYME; THYMIDYLATE SYNTHASE; VERAPAMIL;

APOPTOSIS; CANCER; CELL PROLIFERATION; CROSS RESISTANCE; DRUG CONJUGATION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VASCULARIZATION;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 0031843013     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Gerlach JH, Kartner N, Bell DR and Ling V: Multidrug resistance. Cancer Surv 5: 23-45, 1986.
2. Beck WT: The cell biology of multiple drug resistance. Pharmacol 36: 2879-2887, 1987.
3. Kaye SB: The multidrug resistance phenotype. Br J Cancer 58: 691-694, 1988.
4. Lehnert M: Clinical multidrug resistance in cancer. a multifactorial problem. 912-922, 1996.
5. Volm M and Mattern J: Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncogenesis 7: 227-244, 1996.
6. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2609, 1992.
7. Bellamy WT and Dalton WS: Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31: 1-61, 1994.
8. Gros P, Ben Neriah YB, Croop JM and Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731, 1996.
9. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MCDK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
10. Stein WD, Cardarelli CO, Pastan I and Gottesman MM: Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45: 763-772, 1994.
11. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC and Higgins CF: Volume-regulated chloride channels associated with the human multidrug resistance P-glycoprotein. Nature 355: 830-833, 1992.
12. Cole SPC, Bhardway G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deely RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
13. Schepper RJ, Broxterman GL, Scheffer GL, Kaijk P, Dalton WS, van Heijningen HM, van Kalken CK, Slovak ML, De Vries EGE, van der Kalk P, Meijer CJCM and Pinedo HM: Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479, 1993.
14. Kruh GD, Chan A, Myers K, Gaughan K, Miki T and Aaronson SA: Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 54: 1649-1652, 1994.
15. Zaman GJ, Flens MJ, van Leusden MR, de-Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ et al: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
16. Jedlitschky G, Leier I, Buchholz U, Center M and Kepler D: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance associated protein. Cancer Res 54: 4833-4836, 1994.
17. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer 65: 230-237, 1996.
18. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van-der-Valk P and Scheper RJ: Expression of non-P-glycoprotein multidrug resistance associated protein LRP in normal human tissue and tumors. Am J Pathol 148: 877-887, 1996.
19. Scheffer GL, Wijngaard PLF, Flens MJ, Izquierdo MA, Slovak ML,Pinedo HM, Meijer CJ, Clever HC and Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Med 1: 578-582, 1995.
20. Izquierdo MA, van der Zee A, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens HJ, Pinedo HM, Kenemans P et al: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 87: 1230-1237, 1995.
21. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolf SN, Broxterman HJ Scheffer GL, Scheper RJ and Dalton WS: Overexpression of the major vault transporter lung resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 86: 2464-2469, 1996.
22. Volm M ,Mattern J and Koomägi R: Expression of lung resistance protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anti-Cancer Drugs 8: 931-936, 1997.
23. Zijlstra JG, De Jongs S, De Vries EGE and Mulder NH: Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7: 11-18, 1990.
24. Cole SP, Chandra ER, Dicke FP, Gerlach JH and Mirski EL: Non-P-glycoprotein-mediated multidrug-resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345-3352, 1991.
25. Beck WT, Danks MK, Wolverton JS, Kim R and Chen M: Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 33: 113-127, 1993.
26. Tew KD and Klapper ML: Glutathione S-transferase and anticancer drug resistance. In: Mechanisms of drug resistance in neoplastic cells. Wolley PV and Tew KD (eds), New York, Academic Press, pp 141-159, 1988
27. Volm M, Mattern J and Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-π in human lung tumors. Cancer 70: 764-769, 1992.
28. Volm M and Mattern J: Detection of multiple mechanisms in untreated human lung cancer. Onkologie 16: 189-194, 1993.
29. Oberli-Schrämmli AE, Joncourt F, Stadler M, Altermatt HJ, Buser K, Ris HB, Schmid U and Cerny T: Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int J Cancer 59: 629-636, 1994.
30. Volm M, Mattern J and Samsel B: Overexpression of P-glycoprotein and glutathione S-transferase-π in resistant non-small cell lung carcinomas of smokers. Br J Cancer 64: 700-704, 1991.
31. Sassone-Corsi P, Lamph HW, Kamps M and Verma IM: Fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell 54: 553-563, 1988.
32. Angel P and Karin M: The role of jun, fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
33. Teeter LD, Eckersberg T, Tsai Y and Kuo MT: Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Diff 2: 429-437, 1991.
34. Xia CL, Cowell IG, Dixon KH, Pemble SE, Ketterer B and Taylor JB: Glutathione S-transferase-π Its minimal promoter and downstream cis-acting element. Biochim Biophys Res Commun 176: 233-240, 1991.
35. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jahen S and Tritton TR: Human multidrug resistance KB cells overexpresses protein kinase C: Involvement in drug resistance. Cancer Commun 1: 285-292, 1989.
36. Volm M and Pommerenke EW: Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res 15: 463-466, 1995.
37. Chambers TC, M Avoy EM, Jakobs JW and Eilon G: Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679-7686, 1990.
38. Sahyoun N, Wolf M, Besterman J, Hsiele TS, Sander M, Le Vine III H, Chang KJ and Cuatrecasas E: Protein kinase C phosphorylates topoisomerase II.Topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 83: 1603-1607, 1986.
39. Tanaguchi H and Pyerin W: Glutathione S-transferase is an in vitro substrate of Ca++-phospholipid-dependent protein kinase (protein kinase C). Biochim Biophys Res Commun 162: 903-907, 1989.
40. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
41. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Increased accumulation of vincristine and adriamycin in drug resistance tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
42. Yusa K and Tsuruo T: Reversal mechanism of multidrug resistance by verapamil. Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5002-5006, 1989.
43. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
44. Bellamy WT and Dalton WS: Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31: 1-61, 1994.
45. Ford JM: Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 9: 337-361, 1995.
46. Slater LM, Murray SL, Wetzel MW, Wisdom RM and DuVall EM: Verapamil restoration of doxorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 70: 1131-1134, 1982.
47. Tsuruo T: Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67: 889-894, 1983.
48. Skovsgaard T: Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res 40: 1077-1083, 1880.
49. Slater LM, Sweet P, Stupecky M, Wetzel MV and Gupta S: Cyclosporine A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54: 235-238, 1986.
50. Tsuruo H, Iida H, Kitatani Y, Yokota K, Tsukagoshi S and Yakurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res 44: 4303-4307, 1984.
51. Seeber S, Osieka R, Schmidt CG, Achterrath W and Crooke ST: In vivo resistance towards anthracyclines, etoposide, and cis-diamine-dichloroplatinum (II). Cancer Res 42: 4719-4725, 1982.
52. Cornwell MM, Pastan I and Gottesman, MM: Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles ar inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
53. Safa AR Mehta ND and Agresti M: Photoaffinity labelling of P-glycoprotein in multidrug resistant cells with photoactive analogs of colchicine. Biochem Biophys Res Commun 162: 1402-1408, 1989.
54. Naito M and Tsuruo: Competive inhibition by verapamil of ATP-dependent light affinity vincristine binding to the plasma membrane of multidrug-resistance K562 cells without calcium ion involvement. Cancer Res 49: 1452-1455, 1989.
55. Pommerenke EW, Osswald H, Hahn EW and Volm M: Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells. Cancer Letters 55: 17-23, 1990.
56. Chakrabarty S and Huang S: Modulation of chemosensitivity in human colon carcinoma cells by down-regulating protein kinase C-alpha expression. J Exp Ther Oncol 1: 218-221, 1996.
57. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH and Glazer RI: Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3: 181-189, 1991.
58. Dong Z, Ward NE, Fan D, Gupta KP and O'Brian CA: In vitro model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39: 563-569, 1991.
59. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M and Kuvano M: Circumvention of multiple drug resistance in human cancer cells by chloridazine, trifluoperazine and chlorpromazine. J Natl Cancer Inst 76: 839-844, 1986.
60. Sato W, Yusa K, Naito M and Tsuruo T: Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in mutidrug-resistant cells. Biochem Biophys Res Commun 173: 1252-1257, 1990.
61. Sampson KE, Wolf CL and Abraham I: Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 58: 7-14, 1993.
62. Ma L, Krishnamachary N and Center MS: Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-3343, 1995.
63. Gekeler V, Boer R, Ise W, Sanders KH, Schachtele C and Beck J: The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 206: 119-126, 1995.
64. Van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pinedo HM and Scheper RJ: Distribution of multidrug resistance associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1: 56-64, 1990.
65. Volm M, Pommerenke EW, Efferth T, Löhrke H and Mattern J: Circumvention of multidrug resistance in human kidney and kidney carcinoma in vitro. Cancer 67: 2484-2489, 1981.
66. Donenko FV, Efferth T, Mattern J, Moroz LV and Volm M: Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil. Chemotherapy 37: 57-61, 1991.
67. Milroy R, Plumb J, Banham SW and Kaye SB: Verapamil decreases the sensitivity to adriamycin of an adherent small cell lung cancer cell line in vitro. Br J Cancer 58: 245, 1988.
68. Herzog CE, Tsokos M, Bates SE and Fojo AT: Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268: 2946-2952, 1993.
69. Hamada H and Tsuruo T: Functional role of the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
70. Tsuruo T, Hamada H, Sato S and Heike Y: Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 80: 627-631, 1989.
71. Heike Y, Hamada H, Inamura N, Sone S, Ogura T and Tsuruo T: Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells. Jpn J Cancer Res 81: 1155-1161, 1990.
72. Efferth T, Lathan B and Volm M: Selective growth inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4. Br J Cancer 64: 87-89, 1991.
73. Fitzgerald DJ, Willingham MG, Cardarelli CO, Tsuruo T, Hamada T, Gottesman MM and Pastan I: A monoclonal antibody-Pseudomonas exotoxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84: 4288-4292, 1987.
74. Efferth T and Volm M: Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50: 303-308, 1993.
75. Van Dijk J, Tsuruo T, Segal DM, Bolhuis RHL, Colognola R, van de Griend RJ, Fleuren GJ and Warnaar SO: Bispecific antibodies reactive with the multidrug-resistance related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int J Cancer 44: 738-743, 1989.
76. Naito M, Tsuge H, Kuroko C, Koyama T, Tomida A, Tatsuda T, Heike Y and Tsuruo T: Enhancement of cellular accumulation of cyclosporin A by anti-P-glycoprotein monoclonal antibody MRK16, and synergistic modulation of multidrug resistance. J Natl Cancer Inst 85: 311-316, 1993.
77. Naito M, Tsuge H, Kuroko C, Tomida A and Tsuruo T: Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti P-glycoprotein monoclonal antibody MRK16. Jpn J Cancer Res 84: 489-492, 1993.
78. Meyers MB, Merluzzi VS, Spengler BA and Biedler JL: Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci USA 83: 5521-5525, 1986.
79. Meyers MB, Shen WPV, Spengler BA, Ciccarone V, O'Brian J, Donner DB, Furth ME and Biedler JL: Epidermal growth factor receptor in multidrug resistant human neuroblastoma cells. J Cell Biochem 38: 87-97, 1988.
80. Efferth T and Volm M: Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detection and Prevention 16: 237-243, 1992.
81. Volm M: P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 13: 375-378, 1993.
82. Volm M, Kästel M, Mattern J and Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase π and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinoma. Cancer 71: 3981-3987, 1993.
83. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983.
84. Efferth T and Volm M: Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol and Tumor Pharmacol 9: 11-19, 1992.
85. Volm M and Efferth T: Resistenzüberwindung bei Tumoren. Dtsch med Wschr 119: 475-479, 1994.
86. Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama KZ, Kurosawa Y and Tsuruo T: Mouse human chimeric antibody against the multidrug transporter P-glycoprotein. Cancer Res 50: 3167-3171, 1990.
87. Crooke ST: Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32: 329-376, 1992.
88. Walder RY and Walder JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85: 5011-5015, 1988.
89. Wickstrom E, Bacon TA and Wickstrom EL: Down-regulation of c-Myc antigen expression in lymphocytes of Eμ-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 52: 6741-6745, 1992.
90. Vasanthakumar and Ahmed NK: Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun 1: 225-232, 1989.
91. Jaroszewski JW, Kaplan O, Syi J-L, Sehested M, Faustino PJ and Cohen JS: Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun 2: 287-294, 1990.
92. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T and Parmiani G: Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46: 727-732, 1990.
93. Thierry AR, Rahman A and Dritschilo A: Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 190: 952-960, 1993.
94. Masanek U, Stammler G and Volm M: Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC-isoenzymes with antisense-oligonucleotides. J Exp and Oncology (in press).
95. Rossi JJ, Cantin EM, Sarver N and Chang PF: The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacol Ther 50: 245-254, 1991.
96. James HA and Gibson I: The therapeutic potential of ribozymes. Blood 91: 371-382, 1998.
97. Kobayashi H, Dorai T, Holland JF and Ohnuma T: Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett 319: 71-74, 1993.
98. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirching C and Hermann F: Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13: 4645-4652, 1994.
99. Holm PS, Scanlon KJ and Dietel M: Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line [EPP85-181RDB] by introduction of a hammerhead ribozyme. Br J Cancer 70: 239-243, 1994.
100. Palfner K, Kneba M, Hiddemann W and Bertram J: Improvement of hammerhead ribozymes cleaving mdr-1mRNA. Biol Chem Hoppe Seyler 376: 289-295, 1995.
101. Scanlon KJ, Ishida H and Kashani-Sabet M: Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci USA 91: 11123-11127, 1994.
102. Christoffersen RE and Morr JJ: Ribozymes as human therapeutic agents. J Med Chem 38: 2023-2037, 1995.
103. Sinn H, Schrenk HH, Friedrich EA, Schilling U and Maier-Borst W: Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Nucl Med Biol 17: 819-827, 1990.
104. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst and Heene DL: Plasma protein (albumin) catabolism by the tumor itself-implications in tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26: 77-100, 1997.
105. Pommerenke EW, Sinn H and Volm M: Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin. Eur J Cancer 31A: 283-284, 1995.
106. Benson AB III, Trump DL, Koeller J, Egorin MI, Olman EA, Witte RS, Davis TE and Tormey DC: Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69: 795-799, 1985.
107. Present CA, Kennedy PS, Wiseman C, Gala K, Bouzaglu A, Wyres M and Naessig V: Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 9: 355-357, 1986.
108. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE and Young RC: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641-647, 1987.
109. Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, Midha KK and Ganapathi R: Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor trifluoperazine: a phase I / II trial. J Clin Oncol 6: 880-888, 1988.
110. Hendrick AM, Harris AL and Cantwell BMJ: Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann Oncol 2: 71-72, 1991.
111. Dalmark M, Pals H and Johnsen AH: Doxorubicin in combination with verapamil in advanced colorectal cancer. Acta Oncol 30: 23-26, 1991.
112. Verweij J, Herweijer H, Oosterom R, van der Burg ME, Planting AS, Seynaeve C, Stoter G and Noter K: A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64: 361-364, 1991.
113. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G and Verweij J: Phase II study of combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2: 305-306, 1991.
114. Philip PA, Joel S, Monkman SC, Dolega-Oowski E, Tonkin K, Carmichael J, Idle JR and Harris AL: A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 65: 267-270, 1992.
115. Sridhar KS, Krishan A, Samy TSA, Sauerteig A, Wellham LL, McPhee G, Duncan RC, Anac SY, Ardalan B and Benedetto PW: Prochlorperazine as doxorubicin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother Pharmacol 31: 423-430, 1993.
116. Linn SC, van Kalken CK, van Teilingen O, van der Kalk P, van Groeningen CJ, Kuiper CM, Pinedo HM and Giaccone G: A clinical and pharmacological study of multidrug resistance reversal with vinblastine and hepridil. J Clin Oncol 12: 812-819, 1994.
117. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, De Angelis C and Bunting P: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837-4842, 1993.
118. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan, MN, Halsey J and Sikic BI: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994.
119. Motzer RJ, Lyn P, Fisher P, Lianes P, Ngo RL, Cordon-Cardo C and O'Brian: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958-1965, 1995.
120. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68: 813-818, 1993.
121. Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J and Kaye SB: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771-1777, 1994.
122. Wood L, Palmer M, Hewitt J, Urtasun R, Bruera E, Rapp E and Thaell JF: Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 77: 627-631, 1998
123. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
124. Marie JP, Pastie JN, Coloma F, Faussat-Suberville AM, Delmar A, Rio B, Delmas-Marsalet B, Leroux G, Casasassus P, Boumelou E et al: Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia. Leukemia 7: 821-824, 1993.
125. List AF, Spier C, Greer J, Wolff S, Hutter J Dorr R, Salmon S, Futscher B, Baier M and Dalton W: Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660, 1993.
126. Wilson WH, Bates SE, Fojo A, Bryant G, Zhau Z, Regis JA, Wittes RE, Jaffe ES, Steinberg SM, Herdt J and Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995-2004, 1995.
127. Lum BL, Kaubisch C, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP and Sikic BI: Alteration of etoposide pharmacokinetics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642, 1992.
128. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy PI, Gosland MP, Lum BL and Sikic BI: Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624-1634, 1992.
129. Efferth T, Löhrke H and Volm M: Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9: 1633-1638, 1989.
130. Volm M, Mattern J and Pommerenke EW: Time course of MDR gene amplification during in vivo selection for doxorubicin resistance and during reversal in murine leukemia L1210. Anticancer Res 11: 579-585, 1991.
131. Efferth T, Klett T, Mattern J, Osswald H, Pommerenke EW, Stöhr M and Volm M: Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo. Anticancer Res 11: 1275-1280, 1991.
132. Priwnica-Worms D, Chiu ML, Budding M, Kronauge, JF, Kramer RA and Croop JM: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1993.
133. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rotherford AW and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
134. Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO and Pastan I: Gene transfer of drug resistance genes. Implications for cancer therapy. Ann NY Acad Sci 716: 126-139, 1994.
135. Galski H, Sullivan M, Willingham MC, Chin KV, Gottesman MM, Pastan I and Merlino GT: Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leukopenia. Mol Cell Biol 9: 4357-4363, 1989.
136. Choi, K, Frommel TO, Stern RK, Perez GF, Kriegler M, Tsuruo T and Roninson IB: Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci USA 88: 7386-7390, 1991.
137. Clinical Protocols: Cancer Gene Ther 2: 67-74, 1995.
138. ORDA Reports: Recombinant DNA Advisory Committee (RAC) data management report (Dec 1994). Hum Gene Ther 6: 535-548, 1995.
139. Roth JA and Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? (Review). J Natl Cancer Inst 89: 21-39, 1997.
140. Doroshow JH, Metz MZ, Matsumoto L, Winters KA, Sakai M, Muramatsu M and Kane SE: Transduction of NIH3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad range multidrug resistance. Cancer Res 55: 4073-4078, 1995.
141. Danielson KG, Ohi S and Huang PC: Immunochemical detection of metallothionein in specific epithelial cells of rat organs. Proc Natl Acad Sci USA 79: 2301-2304, 1982.
142. Kasahara K, Fujiwara Y, Nishio K, Ohmori Y, Sugimoto Y, Komiya K, Matsuda T and Saiyo N: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
143. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
144. Pegg AE: Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
145. Brent TP, Houghton PJ and Houghton JA: O6-alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methyl-cyclohexyl)-1-nitrourea. Proc Natl Acad Sci USA 82: 2985-2989, 1985.
146. Kaina B, Fritz G, Mitra S and Coquerelle T: Transfection and expression of human O6-methylguanine-DNA-methyltransferase (MGMT) cDNA in Chinese hamster cells: The role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12: 1857-1867, 1991.
147. Dolan ME, Pegg AE, Moschel RC and Grindey GB: Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 46: 285-290, 1993.
148. Scanlon KJ and Kashani-Sabet: Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A 2780 cells. Proc Natl Acad Sci USA 85: 650-653, 1988.
149. Xu HJ, Hu SX, Cagle PT, Moore GE and Benedict WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51: 2735-2739, 1991.
150. Volm M, Wayss K, Kaufmann M and Mattern J: Pretherapeutic detection of tumor resistance and the results of tumour chemotherapy. Eur J Cancer 15: 983-993, 1979.
151. Schimke RT: Gene amplification in cultured cells. Cell 37: 705-713, 1984.
152. Li GC: Heat shock proteins: Role in thermotolerance, drug resistance, and relationship to DNA topoisomerases. NCI Monogr 4: 99-103, 1987.
153. Huot J, Lambert H, Roy G and Landry J: A typical multidrug-resistance conferred by expression of the human HSP 27 heat shock gene in Chinese hamster cells. Eur J Pharmacol 183: 1632-1633, 1990.
154. Ciocca DR, Fuqua SAW, Lock-Lim S, Toft DO, Welch WJ and McGuire WL: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52: 3648-3654, 1992.
155. Huot J, Roy G, Lambert H, Chretien P and Landry J: Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 51: 245-252, 1991.
156. Oesterreich S, Weng CN, Qui M, Hilsenbeck SG, Osborne CK and Fuqua SAW: The small heat shock protein hsp 27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448, 1993.
157. Valeriote F and van Putten L: Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 3: 2619-2630, 1975.
158. Drewinko B, Patchen M, Yang LY and Barlogie B: Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 41: 2328-2333, 1981.
159. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
160. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia (review). Am J Pathol 147: 545-560, 1995.
161. Volm M, Koomägi R, Mattern J and Stammler G: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer 75: 1774-1778, 1997.
162. Teicher BA: Hypoxia and drug resistance. Cancer Metast Rev 13: 139-168, 1994.
163. Koomägi R, Mattern J and Volm M: Up-regulation of resistance-related proteins in human lung tumors with poor vascularization. Carcinogenesis 16: 2129-2133, 1995.
164. Volm M, Koomägi R and Mattern J: Interrelationship between microvessel density, expression of VEGF and resistance to doxorubicin in non-small cell lung carcinoma. Anticancer Res 16: 213-218, 1996.
165. Dezoise B: Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294, 1994.
166. Stammler G and Volm M: Apoptosis in non-small cell lung cancer as related to drug resistance and prognosis. Apoptosis 1: 95-99, 1996.